Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients

References

• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371:1030–1043.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760–3767.
   PubMed Web of Science ®Google Scholar
• Laport GG, Alvarnas JC, Palmer JM, et al. Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen. Blood. 2008;112:903–909.
   PubMed Web of Science ®Google Scholar
• Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396–4407.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Buck G, et al. UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia. Blood. 2014;123:843–850.
   PubMed Web of Science ®Google Scholar
• Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015;121:4158–4164.
   PubMed Web of Science ®Google Scholar
• Salami K, Alkayed K, Halalsheh H, et al. Hematopoietic stem cell transplant versus chemotherapy plus tyrosine kinase inhibitor in the treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Hematol Oncol Stem Cell Ther. 2013;6:34–41.
   PubMedGoogle Scholar
• Wetzler M, Watson D, Stock W, et al. Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance). Haematologica. 2014;99:111–115.
   PubMed Web of Science ®Google Scholar
• Bassan R, Spinelli O. Minimal residual disease monitoring in Adult ALL to determine therapy. Curr Hematol Malig Rep. 2015;10:86–95.
   PubMed Web of Science ®Google Scholar
• Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013;122:1214–1221.
   PubMed Web of Science ®Google Scholar
• Kuang P, Liu T, Pan L, et al. Sustaining integrating imatinib and interferon-alpha into maintenance therapy improves survival of patients with Philadelphia positive acute lymphoblastic leukemia ineligible for allogeneic stem cell transplantation. Leuk Lymphoma. 2016;57:2321–2329.
   PubMed Web of Science ®Google Scholar
• Lee S, Kim DW, Cho BS, et al. Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia. 2012;26:2367–2374.
   PubMed Web of Science ®Google Scholar
• Olsson L, Johansson B. Ikaros and leukaemia. Br J Haematol. 2015;169:479–491.
   PubMed Web of Science ®Google Scholar
• van der Veer A, Zaliova M, Mottadelli F, et al. IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL. Blood. 2014;123:1691–1698.
   PubMed Web of Science ®Google Scholar
• Kim M, Park J, Kim DW, et al. Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. Bone Marrow Transplant. 2015;50:354–362.
   PubMed Web of Science ®Google Scholar
• Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL)). Blood. 2007;110:727–734.
   PubMed Web of Science ®Google Scholar
• Scheuring UJ, Pfeifer H, Wassmann B, et al. Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment. Leukemia. 2003;17:1700–1706.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Lonetti A, Cilloni D, et al. Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method. Haematologica. 2008;93:1814–1821.
   PubMed Web of Science ®Google Scholar
• DeBoer R, Koval G, Mulkey F, et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665. Leuk Lymphoma. 2016;57:2298–2306.
   PubMed Web of Science ®Google Scholar
• Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2016;128:504–507.
   PubMed Web of Science ®Google Scholar
• Georgopoulos K, Bigby M, Wang JH, et al. The Ikaros gene is required for the development of all lymphoid lineages. Cell. 1994;79:143–156.
   PubMed Web of Science ®Google Scholar
• Westman BJ, Mackay JP, Gell D. Ikaros: a key regulator of haematopoiesis. Int J Biochem Cell Biol. 2002;34:1304–1307.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453:110–114.
   PubMed Web of Science ®Google Scholar
• Iacobucci I, Storlazzi CT, Cilloni D, et al. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). Blood. 2009;114:2159–2167.
   PubMed Web of Science ®Google Scholar
• Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. J Clin Oncol. 2009;27:5202–5207.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med. 2009;360:470–480.
   PubMed Web of Science ®Google Scholar
• Palmi C, Valsecchi MG, Longinotti G, et al. What is the relevance of Ikaros gene deletions as a prognostic marker in pediatric Philadelphia-negative B-cell precursor acute lymphoblastic leukemia?. Haematologica. 2013;98:1226–1231.
   PubMed Web of Science ®Google Scholar
• Beldjord K, Chevret S, Asnafi V, et al. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia. Blood. 2014;123:3739–3749.
   PubMed Web of Science ®Google Scholar
• Ribera J, Morgades M, Zamora L, et al. Prognostic significance of copy number alterations in adolescent and adult patients with precursor B acute lymphoblastic leukemia enrolled in PETHEMA protocols. Cancer. 2015;121:3809–3817.
   PubMed Web of Science ®Google Scholar
• Imamura T, Yano M, Asai D, et al. IKZF1 deletion is enriched in pediatric B-cell precursor acute lymphoblastic leukemia patients showing prednisolone resistance. Leukemia. 2016;30:1801–1803.
   PubMed Web of Science ®Google Scholar
• Churchman ML, Low J, Qu C, et al. Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. Cancer Cell. 2015;28:343–356.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, van der Velden VH, Brüggemann M, et al. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125: 3996–4009.
   PubMed Web of Science ®Google Scholar
• Soverini S, De Benedittis C, Papayannidis C, et al. Drug resistance and BCR-ABL kinase domain mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia from the imatinib to the second-generation tyrosine kinase inhibitor era: the main changes are in the type of mutations, but not in the frequency of mutation involvement. Cancer. 2014;120:1002–1009.
   PubMed Web of Science ®Google Scholar
• Klinger M, Benjamin J, Kischel R, et al. Harnessing T cells to fight cancer with BiTE® antibody constructs-past developments and future directions. Immunol Rev. 2016;270:193–208.
   PubMed Web of Science ®Google Scholar
• Maude SL, Teachey DT, Porter DL, et al. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–4023.
   PubMed Web of Science ®Google Scholar